The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Open accessAbstract
BACKGROUND Clinical remission and low disease activity are essential treatment targets in patients with rheumatoid arthritis. Although moderately active rheumatoid arthritis is common, treatment effects in moderate disease have not been well studied. Additionally, optimum use of biologics needs further investigation, including the use of induction, maintenance, and withdrawal treatment strategies. The aim of the PRESERVE trial was to assess whether low disease activity would be sustained with reduced doses or withdrawal of etanercept in patients with moderately active disease. METHODS In a randomised controlled trial, patients aged between 18 and 70 years with moderately active rheumatoid arthritis (disease activity score in 28 joints [DAS28] >3.2 and ≤5.1) despite treatment with methotrexate were enrolled at 80 centres in Europe, Latin America, Asia, and Australia between March 6, 2008, and Sept 9, 2009. To be eligible, patients had to have been receiving 15-25 mg of methotrexate every week for at least 8 weeks. In an open-label period of 36 weeks, all patients were given 50 mg etanercept plus methotrexate every week. To be eligible for a subsequent double-blind period of 52 weeks, participants had to have achieved sustained low disease activity. These patients were randomly assigned (1:1:1) by an interactive voice-response system to one of three treatment groups: 50 mg etanercept plus methotrexate, 25 mg etanercept plus methotrexate, or placebo plus methotrexate. Patients were stratified in blocks of three by DAS28 response (low disease activity or remission) at week 36. Patients, investigators, data analysts, and study staff were all masked to treatment allocation. The primary endpoint was the proportion of patients with low disease activity at week 88 in the groups given 50 mg etanercept or placebo in the double-blind period. A conditional primary endpoint was the proportion of patients receiving 25 mg etanercept who achieved low disease activity. Modified intention-to-treat populations were used for analyses. This trial is registered with ClinicalTrials.gov, number NCT00565409. FINDINGS 604 (72.4%) of 834 enrolled patients were eligible for the double-blind period, of whom 202 were assigned to 50 mg etanercept plus methotrexate, 202 to 25 mg etanercept plus methotrexate, and 200 to placebo plus methotrexate. At week 88, 166 (82.6%) of 201 patients who had received at least one dose of 50 mg etanercept and one or more DAS28 evaluations had low disease activity, compared with 84 (42.6%) of 197 who had received placebo (mean difference 40.8%, 95% CI 32.5-49.1%; p<0.0001). Additionally, 159 (79.1%) of 201 patients given 25 mg etanercept had low disease activity at week 88 (mean difference from placebo 35.9%, 27.0-44.8%; p<0.0001). INTERPRETATION Conventional or reduced doses of etanercept with methotrexate in patients with moderately active rheumatoid arthritis more effectively maintain low disease activity than does methotrexate alone after withdrawal of etanercept. FUNDING Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationThe Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Self-citationEmery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
Self-citationKremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Self-citationWelsing, P. M. J., Van Gestel, A. M., Swinkels, H. L., Kiemeney, L. A. L. M., & Van Riel, P. L. C. M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2009::aid-art349>3.0.co;2-l · Cited by 498
Stoffer, M. A., Schoels, M. M., Smolen, J. S., Aletaha, D., Breedveld, F. C., Burmester, G., Bykerk, V., Dougados, M., Emery, P., Haraoui, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207526 · Cited by 451
Self-citation
Cited by
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Self-citation2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Diagnosis and Management of Rheumatoid Arthritis: A Review
Aletaha, D., & Smolen, J. S. (2018) · JAMA · doi:10.1001/jama.2018.13103 · Cited by 2,313
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationSmolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Self-citation
Metadata
- Authors
- Smolen, J. S., Nash, P., Durez, P., Hall, S., Ilivanova, E., Irazoque-Palazuelos, F., Miranda, P., Park, M.-C., Pavelka, K., Pedersen, R., Szumski, A., Hammond, C., Koenig, A. S., & Vlahos, B.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 381
- Issue
- 9870
- Pages
- 918-929
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2114909821
- Cited by
- 357
- References
- 26
- FWCI
- 36.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61811-x
- The paper
- Smolen, J. S., Nash, P., Durez, P., Hall, S., Ilivanova, E., Irazoque-Palazuelos, F., Miranda, P., Park, M.-C., Pavelka, K., Pedersen, R., Szumski, A., Hammond, C., Koenig, A. S., & Vlahos, B. (2013). Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(12)61811-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.